NK Cell Expansion Kit
The NK Cell Expansion Kit is suitable for the ex vivo culture and expansion of human natural killer (NK) cells. It contains engineered Growth-Arrested NK Feeder Cells and NK Cell Basal Medium. The Growth-Arrested NK Feeder Cells are K562 cells engineered to express membrane bound IL-21, and other components, to drive the robust activation and expansion of NK cells. The kit provides enough growth-arrested feeder cells for a starter population of 1 million purified NK cells or PBMC cells.
Name | Ordering Information |
Human PBMCs | BPS Bioscience #79059 |
Human Peripheral Blood NK Cells, Frozen | BPS Bioscience #78798 |
Anti-NCAM1 Antibody, PE-Labeled | BPS Bioscience #101673 |
Anti-CD3 Antibody, FITC-Labeled | BPS Bioscience #102008 |
500 x CFSE | BPS Bioscience #82177 |
1000x 7-AAD | BPS Bioscience #82178 |
K562 | ATCC #CCL-243 |
eGFP/Firefly Luciferase K562 Cell Line | BPS Bioscience #78911 |
eGFP/Firefly Luciferase RS4; 11 Cell Line | BPS Bioscience #78926 |
Clear-bottom, white 96-well tissue culture-treated plate | Corning #3610 |
U-bottomed 96-well plate | Corning #3799 |
ONE-Step™ Luciferase Assay System | BPS Bioscience #60690 |
Thaw Medium 2 | BPS Bioscience #60184 |
Luminometer |
Catalog # | Name | Amount | Storage |
78912 | Growth-Arrested NK Feeder Cells | 2 million cells/ vial x 5 vials | Liquid Nitrogen |
82164 | NK Cell Basal Medium | 500 ml | 4°C |
90184 | Human Interleukin-2 | 10 µg | -20°C |
NK (natural killer) cells are part of the innate immune system. They function in a histocompatibility complex-independent mode and derive from the hematopoietic lineage. They are the first line of defense against cancer. Expression of marker CD56 correlates with NK cell functionality: the CD56bright subset accounts for about 5% of the population and is less cytotoxic than the CD56dim subset. Cytotoxicity can happen by the release of perforin and granzyme, while activation by KARs (killer activating receptors) leads to release of Fas Ligand, TRAIL (TNF-related apoptosis-inducing ligand) and TNFα (tumor necrosis factor-alpha). In a suppressive tumor microenvironment, NK cells can become inhibited and unable to fight cancer cells. Several clinical trials have focused on using ex vivo generated NK cells alone or in combination with other approaches. NK cells can be generated ex vivo from peripheral blood, umbilical cord blood, iPS cells or immortalized NK cell lines. The ability to generate a number of pure cells high enough for human dosage often requires the use of growth factors such as IL-2 (interleukin 2) or IL-15, and feeder cells. The use of NK cells or CAR (chimeric antigen receptor)-NK cells is an expanding area holding great promise in cancer therapy.
Du N., et al., 2021 Cancers (Basel) 13 (16): 4129.